Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling

Zhou, Xiang; Hofmann, Annika; Vogt, Cornelia; Nerreter, Silvia; Teufel, Eva; Stanojkovska, Emilia; Truger, Marietta; Engel, Benedict; Barcic, Anastasia; Peter, J. Hotez; Riedhammer, Christine; Steinhardt, Maximilian; Xiao, Xianghui; Hornburger, Hannah; Han, Seungbin; Haertle, Larissa; Munawar, Umair; Mersi, Julia; Haferlach, Claudia; Einsele, Hermann; Rasche, Leo; Kortuem, K. Martin

doi:10.1182/blood-2022-163848

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analysen der Arbeitsgruppe um Kortüm zeigten, dass Patienten, die mittels der kombinierten Techniken FISH und SKY92 jeweils einer Hochrisikogruppe zugeordnet werden konnten, ein signifikant schlechteres PFS und OS gegenüber den Einfach-Hochrisikogruppen hatten und somit eine Ultra-Hochrisikogruppe bilden [4]. Diese Gruppe benötigte demnach eine besonders intensive Therapie und ein zeitnahes Monitoring im Krankheitsverlauf.…”

Section: Dgho-jahrestagung: Herausforderung Zytogenetische Diagnostikunclassified

DGHO-Jahrestagung: Herausforderung zytogenetische Diagnostik

Maugg

2024

Onkologische Welt

View full text Add to dashboard Cite

show abstract

Section: Dgho-jahrestagung: Herausforderung Zytogenetische Diagnostikunclassified

DGHO-Jahrestagung: Herausforderung zytogenetische Diagnostik

Maugg

2024

Onkologische Welt

View full text Add to dashboard Cite

show abstract

Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T‐cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study

Zhou,

Wagner,

Scheller

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

SummaryBiomarkers for cytopenias following CAR T‐cell treatment in relapsed/refractory (RR) multiple myeloma (MM) are not completely defined. We prospectively analysed 275 sequential peripheral blood (PB) samples from 58 RRMM patients treated with BCMA‐targeted CAR T cells, and then divided them into three groups: (i) baseline (before leukapheresis), (ii) ≤day+30, and (iii) >day+30 after CAR T‐cell therapy. We evaluated laboratory data and performed flow cytometry to determine the (CAR) T‐cell subsets. Baseline hyperferritinaemia was a risk factor for long‐lasting grade ≥3 anaemia (r = 0.47, p < 0.001) and thrombocytopenia (r = 0.44, p = 0.002) after CAR T‐cell therapy. Low baseline haemoglobin (Hb) and PLT were associated with long‐lasting grade ≥3 anaemia (r = −0.56, p < 0.001) and thrombocytopenia (r = −0.44, p = 0.002) respectively. We observed dynamics of CAR‐negative T‐cell subsets following CAR T‐cell infusion. In the late phase after CAR T‐cell therapy (>day+30), CD4Tn frequency correlated with anaemia (r = 0.41, p = 0.0014) and lymphocytopenia was related to frequencies of CD8+ T cells (r = 0.72, p < 0.001) and CD8Teff (r = 0.64, p < 0.001). CD4Tcm frequency was correlated with leucocytopenia (r = −0.49, p < 0.001). In summary, preexisting cytopenias and hyperferritinaemia indicated long duration of grade ≥3 post‐CAR T‐cell cytopenias. Prolonged cytopenia may be related to immune remodelling with a shift in the CAR‐negative T‐cell subsets following CAR T‐cell therapy.

show abstract

Current Main Topics in Multiple Myeloma

Morè¹,

Corvatta²,

Manieri³

et al. 2023

Cancers

View full text Add to dashboard Cite

Multiple Myeloma (MM) remains a difficult to treat disease mainly due to its biological heterogeneity, of which we are more and more knowledgeable thanks to the development of increasingly sensitive molecular methods that allow us to build better prognostication models. The biological diversity translates into a wide range of clinical outcomes from long-lasting remission in some patients to very early relapse in others. In NDMM transplant eligible (TE) patients, the incorporation of mAb as daratumumab in the induction regimens, followed by autologous stem cell transplantation (ASCT) and consolidation/maintenance therapy, has led to a significant improvement of PFS and OS.; however, this outcome remains poor in ultra-high risk MM or in those who did not achieve a minimal residual disease (MRD) negativity. Several trials are exploring cytogenetic risk-adapted and MRD-driven therapies in these patients. Similarly, quadruplets-containing daratumumab, particularly when administered as continuous therapies, have improved outcome of patients not eligible for autologous transplant (NTE). Patients who become refractory to conventional therapies have noticeably poor outcomes, making their treatment a difficult challenge in need of novel strategies. In this review, we will focus on the main points regarding risk stratification, treatment and monitoring of MM, highlighting the most recent evidence that could modify the management of this still incurable disease.

show abstract

Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling

Cited by 3 publications

References 0 publications

DGHO-Jahrestagung: Herausforderung zytogenetische Diagnostik

DGHO-Jahrestagung: Herausforderung zytogenetische Diagnostik

Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T‐cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study

Current Main Topics in Multiple Myeloma

Contact Info

Product

Resources

About